

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 June 2004 (10.06.2004)

PCT

(10) International Publication Number
WO 2004/047687 A1

(51) International Patent Classification⁷: **A61F 2/06**

(21) International Application Number:
PCT/US2003/037365

(22) International Filing Date:
21 November 2003 (21.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/428,640 22 November 2002 (22.11.2002) US

(71) Applicants: **COOK INCORPORATED** [US/US]; 750 North Daniel's Way, P.O. Box 489, Bloomington, IN 47402-0489 (US). **COOK BIOTECH, INC.** [US/US]; 3055 Kent Avenue, West Lafayette, IN 47906 (US). **OREGON HEALTH AND SCIENCE UNIVERSITY** [US/US]; 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098 (US).

(72) Inventors: **PAVCNIK, Dusan**; 7676 S.W. Skyhar Drive, Portland, OR 97223 (US). **FETTE, Clay, D.**; 1503 Austin Drive, Lebanon, IN 46052 (US). **MEAD, Jason, A.**; 1658

Connemara Road, Indianapolis, IN 46217 (US). **OBER-MILLER, Joseph, F.**; 3115 Courthouse Drive, Apt. 1D, West Lafayette, IN 47906 (US). **PARKER, Fred, T.**; 8164 East State Road 45, Unionville, IN 47468 (US).

(74) Agents: **GODLEWSKI, Richard, J.** et al.; P.O. Box 2269, Bloomington, IN 47402-2269 (US).


(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

[Continued on next page]

(54) Title: STENT TISSUE GRAFT PROSTHESIS



(57) Abstract: A stent tissue graft prosthesis (20) for repairing, excluding and/or reinforcing a vessel, duct and the like in a patient. The prosthesis includes an inner expandable stent (21) of which a tissue graft (24) and preferably a multilayered tissue construct (33) is disposed thereon for application to the host tissue of a vessel, duct and the like. The tissue construct includes an extracellular matrix material (36) such as small intestine submucosa (37) for remodeling the host tissue into the prosthesis. The prosthesis further includes an outer tubular member (25) such as an outer expandable stent (44) for retaining the tissue graft on the inner stent. The ends of the inner and outer stents are coincident with or extend beyond the ends of the tissue graft to prevent eversion or fold back of the tissue graft during withdrawal of a delivery catheter in a placement procedure.

WO 2004/047687 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

- 1 -

STENT-TISSUE GRAFT PROSTHESIS

DescriptionTechnical Field

This invention relates generally to medical devices and, in particular, to a stent and tissue graft prosthesis and to a delivery system for delivering the prosthesis to an implantation site such as, for example, an aneurysm in the vascular system of a human or animal patient.

Background of the Invention

As background, submucosa tissues have been suggested and used as tissue graft materials. For example, U.S. Patent No. 2,127,903 to Bowen describes various tubes for surgical purposes which may be constructed of the submucosa layer of animal intestinal tissue. Bowen teaches constructing the tubes using a multiplicity of tissue ribbons or threads which are wound over a tubular form and dried.

U.S. Patent No. 3,562,820 to Braun describes the use of submucosa or serosa tissues to form prosthesis devices. In one embodiment, Braun describes preparing a tubular prosthesis by drawing submucosa over a tube and drying the tissue. Braun teaches that this procedure may be repeated until the desired wall thickness is obtained.

U.S. Patent No. 4,956,178 to Badylak et al. teaches tissue graft compositions comprising the tunica submucosa of a segment of small intestine of a warm-blooded invertebrate, wherein the tunica submucosa is delaminated from the tunica muscular and at least the luminal portion of the tunica mucosa. Badylak et al. teaches creating tubular constructs by manipulating a sheet of the tissue graft composition to define a cylinder and suturing or otherwise securing the tissue longitudinally.

U.S. Patent No. 6,358,284 to Fearnot et al. describes the preparation of a tubular graft from a purified submucosa sheet, wherein a first and second opposite edge of the sheet are overlapped, and wherein layers in the overlapped region are fixed to another. The Fearnot et al. patent also discloses the potential of having a second layer of submucosa tissue overlying the first layer.

- 2 -

WO 01/10355 published February 15, 2001 describes tubular grafts of biomaterial, such as submucosa, having lumen walls which present no seam edge traversing the entire length of the lumen, for example, wherein the lumen walls present a discontinuous seam. As described, such a device can be made using a biomaterial sheet having a plurality of extensions and a plurality of corresponding apertures. The sheet can be configured as a cylinder and the extensions extended through the apertures in the formation of the tubular medical device.

WO 01/82836 A2 published November 8, 2001 describes an endovascular stent graft with a stent frame having a plurality of stents connected together with a monofilament line. A covering of collagen having an extracellular matrix (ECM), such as small intestine submucosa (SIS) is disposed through the inside and over the outside of the stent frame. The covering is affixed to the stent frame such as by being sutured onto the stent frame at the ends of the stent frame and also at the connections of the stent bodies, such as at eyelets.

U.S. Patent 5,693,085 to Buirge et al. describes a stent with collagen in which the collagen is applied to the outside surface of a vascular stent.

U.S. Patent 5,916,264 to Von Oepen et al. describes a stent graft having two coaxially arranged, radially expanded stents and a flexible, stretchable material layer arranged between the stents. Both stents are directly connected with one another in their end regions and the material layer is formed as a fabric band wound around an inner stent. The material layer is composed of a foil or a fabric from a body compatible material or of a biological fabric. The biological material can include an autologous or homologous vein or artery.

Endoluminal exclusion of an abdominal aortic aneurysm (AAA) by transluminal implantation of stent grafts has in selected cases become an attractive alternative to open surgical aneurysmal repair. Endoluminal exclusion has been done on an elective basis after detailed preoperative visualization and measurements have been made of the aneurysmal and adjacent arterial anatomy. Stent graft systems for both elective and emergency AAA exclusions have been typically constructed with conventional surgical synthetic materials such as

- 3 -

DACRON or polytetrafluoroethylene (PTFE) supported by typically metallic expandable stents.

Conventionally, stent grafts placed within the vascular system include one or more stents of affixed graft material including biological materials in addition to the conventional synthetic materials. As previously suggested, these biological materials can include tissue which is affixed to one or more longitudinally positioned stents using, for example, sutures which are affixed to folded over tissue at the ends of the stents and similarly along the lengths of the stents. As suggested by the Von Oepen patent, stents can be used to sandwich a stretchable material layer arranged longitudinally between the two stents. However, the stents are directly connected with one another at their end regions making the end regions significantly more rigid thereat than the intermediate portion therebetween. Abrupt transitions between the stented and unstented portions can cause significant trauma and undesirable intimal hyperplasia with consequent narrowing of the vessel. This consequence is typically referred to as "edge effect." Attachment sutures or other attachment configurations allow for a leakage of blood through the covering material, thus producing undesirable and/or life-threatening endoleaks. Furthermore, simply covering a stent with a layer of tissue without any attachment thereto allows for the tissue material to be pulled back or everted over itself when a delivery catheter is pulled back over the stent graft at the implantation site. This eversion creates a significant problem in that the aneurysm is no longer excluded and in that the stent graft with its everted tissue material presents a significant problem in its removal.

Summary of the Invention

The foregoing problems are solved and a technical advance is achieved in an illustrative embodiment of a stent and tissue graft prosthesis in which a tissue graft is disposed on a first or inner expandable stent and an outer tubular member such as a second or outer expandable stent is disposed over the tissue graft and around the first expandable stent for retaining advantageously the tissue graft disposed on the inner stent. As a consequence, holes through the tissue graft are advantageously minimized, if not eliminated, and the probability of endoleaks

- 4 -

are significantly lessened. In this preferred illustrative embodiment, the ends of the inner and outer stent along with that of the tissue graft are advantageously aligned to coincide with each other. This alignment further advantageously allows host tissue coming in contact with the tissue graft to remodel and become incorporated into the prosthesis when the tissue graft includes, for example, an extracellular matrix material (ECM) such as small intestine submucosa.

Other embodiments of the present invention include extending the inner expandable stent beyond the end of the tissue graft. However, the outer tubular member is still positioned at least entirely over the tissue graft or extends beyond the ends of the tissue graft so as to advantageously prevent undesirable eversion or displacement of the tissue graft during, for example, placement of the prosthesis and, in particular, when withdrawing a delivery catheter from the prosthesis. Keeping the ends of the inner expandable stent coincident with the ends of the tissue graft prevents the tissue graft from everting or folding into the passage of the inner expandable stent. As a result, the tissue graft is prevented from narrowing the passage or lumen of the vessel and/or creating an edge, shelf, and the like for thrombus and the like to build up on or adhere to. Since the stent tissue graft prosthesis is typically placed in an arterial vessel, pulsatile blood flow can cause the eversion of the tissue graft over either end of the inner expandable stent, which is advantageously prevented when the ends of the inner expandable stent are coincident with or extend beyond the ends of the tissue graft.

The outer tubular member of the tissue stent graft prosthesis can advantageously assume one of several different configurations. In one embodiment, the tubular member includes a perforated tube or sleeve of a polymer material such as polyethyleneterephthalate (PET). The size of the perforations is advantageously selected so as to promote contact with and remodeling of the host vessel tissue therethrough. In the preferred embodiment of the stent tissue graft prosthesis, the tubular member includes a second or outer expandable stent, which can be self-expanding, balloon expandable, or a combination of both. Furthermore, the inner expandable stent can also be self-expanding, balloon expandable, or a combination of both. In the preferred embodiment, the inner and outer expandable

- 5 -

stents each include a plurality of circumferential segments and a plurality of tie bars longitudinal interconnecting the circumferential segments. The circumferential segments advantageously include a serpentine configuration and preferably a zigzag pattern of generally straight struts interconnected by a plurality of bends.

5 The zigzag pattern advantageously provides for a compressed stent diameter, which facilitates loading into a delivery system for delivering the prosthesis to an implantation site. When released, the zigzag pattern can typically expand six or more times its compressed diameter to bring the tissue graft between the inner and outer expandable stents in contact with the vessel wall.

10 The inside and outside diameters of each of the inner and outer expandable stents in a relaxed condition is selected to retain the tissue graft disposed on the inner stent and at the same time apply sufficient outward pressure to maintain the tissue graft in contact with the vessel wall without causing damage to either the tissue graft or the vessel wall. In addition, the diameters can be

15 selected to accommodate different loading procedures and whether the tissue construct is hydrated, lyophilized or a combination of both during the loading procedure.

In a preferred embodiment, the outside diameter of the inner stent is selected to be greater than the inside diameter of the outer stent. This embodiment

20 helps facilitate the loading of a stent and lyophilized tissue graft prosthesis into an introducer or delivery system. This is also applicable to hydrated tissue. The lyophilized tissue graft is preferably selected to have a diameter in between the dimensions of the inner and outer stents and is thus advantageously disposed and retained on the inner stent and in direct contact with the vessel wall.

25 In another embodiment using a hydrated tissue graft, the outer diameter of the inner stent is selected to be less than the inner diameter of the outer stent. Again, the tissue graft is preferably selected to have a diameter in between these two inner and outer stent dimensions. Such an embodiment provides for the loading of a hydrated tissue graft over the inner stent while providing sufficient

30 tolerance for loading the outer stent over the hydrated tissue graft without causing injury or damage thereto. When positioned in an introducer system, there is

- 6 -

always sufficient pressure between the inner and outer stent so as to retain the tissue graft disposed on the inner stent. Typically, it is preferred to oversize the prosthesis approximately 10% to 20%, preferably 10% to 15%, and more preferably 10% with respect to the vessel lumen diameter so as to maintain sufficient outward
5 force on the tissue graft and stents to eliminate or minimize migration of the prosthesis in the implanted vessel. Oversizing the stent tissue graft prosthesis to more than 20% of the vessel diameter can cause trauma to the vessel wall and, in particular, migration of the stent through the vessel wall.

In a preferred and best mode embodiment, the outside diameter of the
10 inner stent is greater than the inside diameter of the outer stent as previously described. However, a dry, laminated, tubular tissue graft construct is inserted into the outer stent, which is preferably nitinol and in a fully martensitic and expanded state. The dry construct is preferably formed by vacuum pressing the water therefrom; however, lyophilization can be utilized to remove the water as well. The
15 inner stent, which is preferably nitinol and in a fully martensitic and compressed state, is inserted into the dry tubular construct with the outer stent therearound. The combination tissue graft construct with the stents therearound is rehydrated and loaded onto the delivery system cannula. The rehydrated construct is compressed, frozen and loaded into the sheath of the delivery system. While frozen
20 or at least still rehydrated, the tissue graft in the delivery system is freeze-dried or evaporative cooled. This tissue graft construct and stent combination is advantageously loaded into a delivery system without tearing the tissue or causing pin holes therein, which can occur when simply loading a lyophilized or dried tissue construct into a delivery system.

25 In yet another embodiment, the inside and outside diameters of the inner and outer expandable stents are selected to be equivalent to exert more compressive force on a hydrated tissue graft or less compressive force on a lyophilized tissue graft.

In another aspect of a preferred embodiment of the stent tissue graft
30 prosthesis of the present invention, the tissue graft preferably includes at least one seamless tube of tissue, tissue including extracellular matrix material and more

- 7 -

preferably a seamless tube of small intestine submucosa for advantageously remodeling host tissue coming in contact therewith. In the preferred illustrative embodiment, the tissue graft includes a multilayer tissue construct including a plurality of seamless tubes of tissue including extracellular matrix material. The

5 construct advantageously includes at least an inner and an outer seamless tube of porcine small intestine submucosa of different nominal diameters, which is typically harvested from at least two different weight juvenile contributors. To advantageously add further strength to the multilayered construct, a sheet of tissue from mature porcine small intestine submucosa tissue will be used. Thus, one

10 preferred construct will include an inner tube of juvenile porcine small intestine submucosal tissue. Next, at least one sheet of mature porcine small intestine submucosal tissue is advantageously wrapped around the inner seamless tube one or more times to add further strength to the construct. In addition, an outer seamless tube of juvenile porcine tissue is disposed over the wrapped sheet of

15 mature porcine tissue. To further bind the construct together, a fibrin and/or fibrinogen glue is applied to the layers of the construct during formation thereof to further bind the layers and construct together. Another preferred method of laminating the construct together is vacuum pressing the ECM layers together. The hydrated construct is then lyophilized to further advantageously concentrate and/or

20 compress the layers of the construct to form a rehydrated wall thickness that is less than the initial hydrated thickness of the pre-lyophilized tissue construct. This advantageously produces a tissue graft that further reduces the wall thickness of the construct and the overall thickness of the stent tissue graft prosthesis of the present invention.

25 To address and avoid potential pinhole leaks in juvenile porcine tissue, at least one sheet of mature porcine tissue is wrapped around a mandril to form preferably a four layer laminated tissue construct. A minimum of one mature porcine tissue sheet or layer is contemplated, but a tissue construct of six or more laminated layers of mature porcine tissue is also contemplated at the other end of

30 the range of tissue layers. However, a construct comprising four layers of mature

- 8 -

porcine tissue represents the preferred, best mode embodiment of the present invention.

5 A further advantage of the stent tissue graft prosthesis of the present invention is that the ends of the inner stent and the outer tubular member and, in particular, the outer expandable stent are preferably not affixed to one another. Although such fixation would initially appear to better contain the tissue graft therebetween, the added stiffness of the end portions of the inner stent and outer member would further traumatize the tissue immediately adjacent and extending beyond the ends of the prosthesis. Such trauma can be minimized by staggering 10 the ends of the inner stent and outer tubular member as previously suggested; however, the tissue graft must not extend beyond the ends of the inner stent and the outer tubular member should fully cover the tissue graft so as to prevent undesirable eversion during the delivery procedure.

Brief Description of the Drawing

15 Fig. 1 depicts a pictorial view of a preferred embodiment of the stent tissue graft prosthesis of the present invention;

Fig. 2 depicts a partial and enlarged pictorial end view of the prosthesis of Fig. 1;

20 Fig. 3 depicts an enlarged and partial pictorial end view of another preferred embodiment of the prosthesis of the present invention in which the distal end of the tissue graft is longitudinally recessed from the coincident stent ends of the inner and outer stents;

25 Fig. 4 depicts an enlarged and partial pictorial end view of still another preferred embodiment of the stent tissue graft prosthesis of the present invention in which the distal end of the outer stent is recessed back from the distal end of the inner expandable stent;

30 Fig. 5 depicts an enlarged and partial pictorial end view of yet another preferred embodiment of the prosthesis of the present invention in which the distal end of the inner stent is recessed back from the distal end of the outer stent and in which the distal end of the tissue graft is recessed longitudinally in and from the distal ends of both the inner and the outer expandable stents;

- 9 -

Fig. 6 depicts an enlarged and transverse cross-sectional view of the prosthesis of Fig. 1 taken along the line 6-6;

Fig. 7 depicts an enlarged and transverse cross-sectional view of a segment of the tissue graft and, in particular, the multilayered tissue construct of Fig. 6;

Fig. 8 depicts an enlarged and transverse cross-sectional view of another embodiment of a segment of the tissue graft and, in particular, the multilayered tissue construct of Fig. 6;

Fig. 9 depicts an enlarged and partially sectioned view of the distal end portion of the prosthesis delivery system of the present invention;

Fig. 10 depicts a pictorial view of yet another embodiment of the stent tissue graft prosthesis of the present invention;

Fig. 11 depicts a pictorial view of still yet another embodiment of the tissue stent graft prosthesis of the present invention;

Fig. 12 depicts a pictorial view of yet still another embodiment of the stent tissue graft prosthesis of the present invention for use, by way of example, in a bifurcated vessel; and

Figs. 13 and 14 depict the endoluminal placement of the prosthesis of the present invention in an abdominal aortic aneurysm.

Detailed Description

Fig. 1 depicts a pictorial view of a preferred illustrative embodiment of stent tissue graft prosthesis 20 of the present invention. In addition, this preferred embodiment depicts the best mode of the present invention. Stent tissue graft prosthesis 20 includes a first or inner expandable stent 21 having a passage 23 extending longitudinally therethrough, a tissue graft 24 disposed on inner stent 21 and a tubular member 25 such as a second or outer expandable stent 44 with a passage 27 extending longitudinally therethrough and disposed over the tissue graft and around the inner expandable stent so as to advantageously retain the tissue graft disposed on the first inner stent. The first or inner expandable stent has a distal inner stent end 28 and a proximal stent end 29. Similarly, tissue graft 24 has a distal graft end 30 and a proximal graft end 31. In like fashion, tubular

- 10 -

member 25 and, in particular, outer expandable stent 44 includes distal tubular or outer stent end 55 and proximal tubular or outer stent end 56. In this preferred and best mode embodiment of the present invention, the tissue graft 24 includes a multilayered tissue construct 33 of which the distal and proximal graft ends 30 and 31 thereof are coincident longitudinally with the respective, coincidentally disposed distal and proximal ends of the inner and outer expandable stents 21 and 44. The distal and proximal ends of tissue graft 24 are coincident with the respective distal and proximal ends of inner stent 21 to prevent the tissue graft from folding over or everting into passage 23 of the inner stent during pulsatile flow of blood when the prosthesis is positioned in, for example, an arterial vessel of a patient. The fold-over or eversion of the tissue graft into the passage or lumen of the inner stent can cause turbulent blood flow and can clearly create a lumen restriction for thrombus to build up on and further restrict blood flow. This can occur at either end of the prosthesis during antegrade and retrograde pulsatile blood flow. In addition, the inner expandable stent applies outward radial expansion force against the tissue graft and outer stent to keep the tissue graft in direct physical contact with the wall of a vessel when implanted therein. The direct contact of the tissue graft with that of the vessel wall facilitates remodeling of the host vessel wall cells or tissue into the tissue graft particularly when the tissue graft includes extracellular matrix material such as small intestine submucosa.

The distal and proximal tubular or outer stent ends 55 and 56 are disposed coincidentally with the respective distal and proximal ends of the inner expandable stent and the tissue graft. The ends of the tubular member or outer stent are coincident with the tissue graft so as to preferably prevent eversion or fold-over of the tissue graft during withdrawal of a delivery catheter that is used to place the prosthesis at the placement site in a vessel. Should the outer tubular member or stent not be positioned over the entire length of the tissue graft, there can be sufficient adhesion between the tissue graft and delivery catheter so as to evert, fold over or pull back the tissue graft over itself and the inner stent as the delivery catheter is pulled back from the prosthesis. The outer tubular member or stent prevents such eversion, fold over or pull back of the tissue graft particularly

- 11 -

at the ends and further maintains the uniform wall thickness of the prosthesis along its entire length.

Fig. 2 depicts a partial and enlarged pictorial end view of prosthesis 20 of Fig. 1. In this enlarged end view of the prosthesis, outer tubular member 25 such as outer expandable stent 44 includes a plurality of circumferential cell segments 57 including distal end cell segment 61, flexible interconnection cell segment 71, and hoop cell segment 72 that extend longitudinally along the length of the stent. A plurality of tie bars 60 extend longitudinally along the outer stent and interconnect circumferential segments 57. A detailed description of the inner and outer stents including circumferential segments interconnected by longitudinally extending tie bars is disclosed in U.S. Patent Application Serial No. 10/267,385, Publication No. U.S. 2003-0088310 A1, filed October 9, 2002, and entitled "Cannula Stent," which is incorporated by reference herein in its entirety. The flexible interconnection cell segments provide lateral flexibility for the stent, whereas the end and hoop cell segments have higher radial strength for maintaining the vessel open. However, the distal and proximal end cell segments 61 and 62 (Fig. 1) preferably exert less outward radial force so as to advantageously minimize "edge effect" trauma due to the abrupt change in force between the stented and unstented vessel wall. Each segment includes a serpentine pattern 50 of which the end and hoop cell segments include a serpentine pattern known as a zigzag or Z pattern 59.

Inner expandable stent 21 is similar to outer expandable stent 44 and includes a plurality of circumferential cell segments 65 including distal end cell segment 63, flexible interconnection cell segment 64, and hoop cell segment 42 (not shown). As previously suggested, the circumferential segments 65 and 57 of respective inner and outer expandable stents 21 and 44 each include a serpentine zigzag pattern of straight struts 51 interconnected by a plurality of bends 52. This well-known and commercially available zigzag pattern was first developed in a stent commonly known as the Gianturco Z-stent as described in U.S. Patent No. 4,580,568 and incorporated herein by reference. The inner and outer expandable stents are also known as ZILVER® stents and commercially available from Cook

- 12 -

Incorporated, Bloomington, IN. One or more eyelets 66 extend from the ends of the inner and outer expandable stents and include a radiopaque material such as gold to provide radiographic visualization of the stent's position when placed in the vessel of a patient. As also previously suggested, the expandable stents can be either self-expanding, balloon expandable, or a combination of both. Self-expanding stents are typically formed from a spring-like metal such series 316L stainless steel or a shape memory alloy such as nickel titanium commonly referred to as nitinol. However, any spring-like biocompatible material is suitable so as to provide outward radial force to keep the tissue graft in contact with the vessel wall. Similarly, balloon expandable stents can be formed from stainless steel or other biocompatible materials. Either the self-expanding or balloon expandable materials can be formed from a tube or cannula or formed from a filament of spring-like material having, for example, a circular, triangular or other suitable cross-sectional shape. It is also contemplated that any expandable stent can be used with this invention and that the invention is not limited to serpentine.

Fig. 3 depicts a partial and enlarged pictorial end view zigzag, or Z stent of another preferred embodiment of prosthesis 20 of the present invention in which distal end 30 of tissue graft 24 is longitudinally recessed from distal stent end 28 of inner stent 21 that is coincident with distal stent end 55 of outer stent 44. In this embodiment, the distal end of the tissue graft is approximately 1 cm in from the coincident distal ends of the inner and outer stents. This places the distal end of the tissue graft approximately in the middle of the straight struts of outer distal end cell 61 and inner distal end cell 63. As a result, this lessens the amount of force applied at the end of the stents so as to again minimize "edge effect" at the transition of the stented and unstented portions of the vessel. In addition, the radiopaque markers and eyelets are coincident with one another on the inner and outer stent ends. However, the circumferential orientation of the eyelets and end cell struts can be rotated and staggered so as to further distribute the force applied to the captured distal end of the tissue graft.

Fig. 4 depicts an enlarged and partial pictorial end view of still another preferred embodiment of stent 20 of the present invention in which the distal end

- 13 -

of outer stent 44 is recessed back from the distal end of inner stent 21, and the distal end 30 of tissue graft 24 is recessed longitudinally in and from the distal ends of both inner and outer expandable stents 21 and 44. As previously detailed, the distal end 30 of the tissue graft is placed in the middle of the straight struts of the distal end cell 61. This configuration is to further distribute the radial force of the prosthesis longitudinally along the distal and proximal end portions of the prosthesis. Alternatively, the distal end 30 of tissue graft 24 can be made coincident with distal end 55 of the outer stent. However, the overriding concern is that the longitudinal force is distributed along the end portions of the prosthesis. Furthermore, the outer tubular member of the stent should completely cover the tissue graft so as to prevent an eversion of the tissue graft during withdrawal of the delivery catheter during placement in a vessel. Likewise, the end of the inner stent must be at least coincident with or extend beyond the end of the tissue graft to insure that the ends of the tissue graft do not evert or fold back into the lumen of the prosthesis and vessel and cause a restriction or resistance to blood flow.

Fig. 5 depicts an enlarged and partial pictorial end view of yet another preferred embodiment of stent 20 of the present invention in which the distal end of inner stent 21 is recessed back from the distal end of outer stent 44, and the distal end 30 of tissue graft 24 is recessed longitudinally in and from the distal ends of both inner and outer expandable stents 21 and 44. In this embodiment, the distal end 30 of the tissue graft is placed in the middle of the straight struts of distal end cell 63 of inner stent 21. As a result, distal end 30 of the tissue graft is supported by flexible interconnection cell 71 of outer stent 44. This configuration is another embodiment for distributing the outward radial force of the prosthesis longitudinally along the distal and proximal end portions of the prosthesis. As with the embodiment of Fig. 4, the overriding concern is that the longitudinal force is distributed about the end portions of the prosthesis. Furthermore, the inner and outer stents should completely cover the tissue graft so as to prevent eversion of the tissue graft either into the prosthesis or during withdrawal of the delivery sheath during placement in the vessel. Fig. 6 depicts an enlarged and transverse cross-sectional view of prosthesis 20 of Fig. 1 taken along the line 6-6. The

- 14 -

innermost ring depicts inner expandable stent 21 with tubular wall 22 having, for example, a wall thickness of approximately 215 microns and passage 23 extending longitudinally therethrough. The outermost ring represents tubular member 25 and, in particular, outer expandable stent 44 with tubular wall 26 having a thickness of approximately 215 microns and passage 27 extending longitudinally therethrough. As previously suggested, tubular member 25 can be a flexible tube of polymer material such as PET with perforations therein for allowing the tissue graft to contact a vessel wall. Disposed or sandwiched between inner and outer stents 21 and 44 is tissue graft 24 and, in particular, multilayered tissue construct 33. Construct 33 has a wall 53 with a thickness of approximately 500-600 microns depending on the number of layers thereof and passage 54 extending longitudinally therethrough. In this embodiment, the multilayered tissue construct includes five layers of tissue each having extracellular matrix material. The construct also includes at least one innermost seamless tube of tissue 32 of, for example, juvenile porcine small intestine submucosa (SIS). Since the juvenile small intestine submucosa does not have the density and strength of mature small intestine submucosa, a plurality of seamless tubes of juvenile SIS tissue of different diameters is contemplated.

In a preferred embodiment of the tissue construct, a first or innermost seamless tube of juvenile SIS tissue 32, a second or intermediate seamless tube of juvenile SIS tissue 67 and an outermost seamless tube of SIS tissue 68 constitute a plurality of seamless tubes of tissue 34 that would typically have a wall thickness equivalent to that of one layer of mature porcine SIS tissue. By way of example, each seamless tube of SIS tissue 32, 67, and 68 has an average thickness of approximately 100 microns and ranges in thickness from 80 to 125 microns. The thickness of a sheet of mature porcine SIS tissue material has an average thickness of approximately 250 microns and ranges in thickness from 200 to 300 microns. Thus, a tissue construct comprising three seamless tubes of juvenile porcine SIS tissue should have more than sufficient strength to withstand nominal blood pressures of typically 120 mm of mercury. This embodiment including a lyophilized three-layer tissue construct is relatively easy to load into a delivery system.

- 15 -

However, assembly and loading of the prosthesis 20 using inner and outer stents of various diameters and a lyophilized tissue construct of three tubes of juvenile porcine SIS tissue can cause pin holes or tears in the tissue construct unless extra care and special attention is given during the assembly and loading process.

5 However, a vacuum pressed method of assembly can also be used on this, as well as other constructs of the ECM construct, to minimize, if not eliminate, pinholes or tears during prosthesis assembly.

Accordingly, to provide further strength to the tissue construct and minimize, if not eliminate, fluid leaks, tissue construct 33 of the embodiment of Fig. 10 6 further includes two layers 69 and 70 of mature tissue graft material such as mature porcine small intestine submucosa which also includes extracellular matrix material. This extracellular matrix material facilitates remodeling of tissue coming in contact therewith such as the endothelial cells of a blood vessel. As a result, this five-layer tissue graft construct provides more than sufficient strength and 15 durability to exclude, for example, an aneurysm in a blood vessel wall. Alternatively, a lyophilized multilayered tissue construct of four or five seamless tubes of juvenile porcine SIS is also contemplated to withstand damage during the loading process into a delivery catheter. In addition, inner and outer seamless tubes of juvenile SIS tissue and two layers of mature porcine SIS tissue is further 20 contemplated for use in the prosthesis of the present invention. A detailed description of a multilayered tissue construct is disclosed in U.S. Provisional Application Ser. No. 60/408,914, filed September 6, 2002, entitled "Tissue Graft Prosthesis Devices Containing Juvenile or Small Diameter Submucosa," also filed as PCT International Serial No. PCT/US03/27695, filed September 4, 2003, which 25 are incorporated by reference herein in its entirety. SIS tissue or SIS tissue constructs are commercially available from Cook Biotech, West Lafayette, IN.

In addition, a description of a preferred extracellular matrix material such as small intestine submucosa is described in U.S. Patent No. 6,206,931 B1, entitled "Graft Prosthesis Materials," which is incorporated by reference herein in its 30 entirety. The SIS material harvested from porcine for use in the present invention as described therein includes disinfecting and then stripping the various layers of

- 16 -

the small intestine to produce an extracellular matrix SIS material that has extremely low endotoxin levels. Tissue construct 33 is formed per the 60/408,914 disclosure, using for example, fibrin or fibrinogen glue to adhere the various layers of the construct together. In addition, when the construct is lyophilized, a construct
5 typically having an initial hydrated wall thickness of approximately 800 microns reduces in thickness when re-hydrated to a thickness of approximately 500-600 microns.

Fig. 7 depicts an enlarged and transverse cross-sectional view of a segment of tissue graft 24 and, in particular, multilayered tissue construct 33 of Fig.
10 6. This cross-sectional view of the tissue construct illustrates how the inner edge 88 of first mature tissue layer 69 is positioned with respect to outer edge 87 of second mature tissue layer 70. As depicted, inner edge 88 is one edge of a sheet of mature SIS tissue which is positioned longitudinally along the length of the construct over seamless tubes of juvenile SIS tissue 32 and 67. The sheet of mature
15 SIS tissue is then wrapped twice around the circumference of the seamless tubes 32 and 67. Longitudinally extending outer edge 87 of the same sheet of mature SIS tissue is then positioned to abut a line extending from the center of the tubular construct that also abuts inner edge 88 of first mature SIS layer 69. As a result, a single layer of the mature tissue separates the inner and outer edge of the mature
20 tissue sheet. To maintain the position of the sheet of the mature SIS tissue, fibrin or fibrinogen glue is applied to the surfaces of the sheet. After the mature sheet of SIS tissue is wrapped around as two layers, the outermost seamless tube of juvenile SIS tissue 68 is positioned over the wrapped sheet of mature SIS tissue.

In a best mode embodiment, one or more hydrated sheets of mature SIS
25 tissue are wrapped around a mandrel to form a laminated construct with preferably four layers of the tissue sheet. The number of hydrated sheets is dependent on the size and, in particular, the circumference of the construct. The SIS tube is manufactured as follows: Sow weight SIS is obtained in hydrated form. This material is laid down with the longitudinal axis aligned horizontally. A rigid rod or
30 mandrel is then placed onto the SIS at the top edge. The top edge of the SIS is then carefully pulled over onto the rigid mandrel and made as smooth and straight as

- 17 -

possible. The material is then rolled onto the mandrel in overlapping fashion until the desired number of layers is obtained. Multiple pieces of SIS can be used to obtain the desired number or layers or thickness of material. After the material has been rolled onto the mandrel, this system (mandrel plus SIS) is placed into a commercially available vacuum pressing apparatus. One such vacuum pressing apparatus is commercially available from Zip-Vac East, Incorporated, Kennesaw, Georgia. The vacuum pressing apparatus is a flexible chamber that has a vacuum drawn on it, which pulls the flexible boundaries of the chamber onto and around the mandrel/SIS. Due to the vacuum, the water is removed from the SIS, while the sides press against and around the SIS. This results in a dry, well-laminated tube of SIS material. The SIS tube is then removed from the mandrel, and the edges are trimmed to the desired length.

Further processing is required to manufacture an abdominal aortic aneurysm (AAA) stent-graft. The dry SIS tube is inserted into the desired diameter ZILVER (or other design) stent. Another stent is then deployed inside of the SIS tube. Resultingly, there is a stent on the inside, a dry SIS tube, and a stent on the outside. This construct is then rehydrated in high purity water for at least 10 minutes. The now rehydrated construct (stent/SIS/stent) is then loaded onto a delivery system cannula. It is then compressed with uniform radial force. While still compressed, the construct is frozen. After freezing, the construct is loaded into the sheath of the delivery system. While still frozen, or at least while still rehydrated, the entire system is then freeze-dried (lyophilized or evaporative cooled). This freeze-dried system is then sent to sterilization and once sterile is ready for distribution. When assembling the tissue graft construct and stents, it is preferred to have, for example, nitinol stents in a fully martensitic state so as not to introduce stress-induced martensite in the nitinol material. This is easily accomplished by placing the stent in liquid nitrogen to cool the nitinol below its martensitic final temperature. The temperature of the stents can be raised above 0° C but below austenite start temperature so as to load hydrated SIS laminated constructs therein or therearound.

- 18 -

In addition, a larger diameter tube can possibly be manufactured by using tube-form SIS material. If the desired diameter of SIS tube is similar to the diameter of the tube-form SIS material, pieces of tube-form SIS can be placed onto a rigid mandrel. Multiple pieces of tube-form material can be added until the
5 desired number of layers or thickness of the SIS device is obtained. After all of the tube-form SIS has been placed onto the mandrel, the mandrel and SIS is vacuum pressed as described before. Other manufacturing processes after vacuum pressing are identical to that listed above. The advantage of using tube-form SIS material is that a seamless inner lumen will result.

10 Also, an AAA stent graft can be manufactured using only one ZILVER (or other) stent, and one tube of SIS. This system would require the SIS to be affixed to the stent, for example, by glue or suture.

Also, an AAA stent graft can be manufactured by vacuum pressing the SIS component directly onto one stent. After drying, this construct can be
15 rehydrated and compressed, loaded, and freeze dried. It is also possible to vacuum press the SIS material between two stents, further reducing the profile of the resultant device.

Fig. 8 depicts an enlarged and transverse cross-sectional view of another embodiment of a segment of tissue graft 24 and, in particular, multilayered tissue
20 construct 33 of Fig. 6. In this embodiment, the single sheet of mature SIS tissue is wrapped more than twice around the first and second seamless tubes 32 and 67 of juvenile SIS tissue. In particular, the inner edge of first layer 69 is longitudinally positioned along the construct and then wrapped two and one-fourth to two and one-half times around the inner seamless tubes. This is also preferred with the
25 previously described best mode embodiment. As a result, outer edge 87 of the single sheet of the mature SIS tissue is no longer radially aligned with inner edge 88 of the sheet. However, the additional one quarter to one-half wrap of the single sheet provides a third layer to provide additional strength over inner edge 88 of the sheet of tissue. This clearly provides a minimum of two layers of mature tissue
30 over the inner edge of the sheet. Again, fibrin or fibrinogen glue can be applied to the sheet to help position the wrapping of the mature SIS sheet around the inner

- 19 -

seamless tubes. Outermost seamless tube 68 is then positioned over the wrapped mature SIS tissue sheet. This outermost seamless tube keeps the wrapped sheet of mature SIS tissue in place.

Returning to Fig. 6, inner expandable stent 21 has an inside diameter 45 and outside diameter 47. Similarly, outer expandable stent 44 has an inside diameter 46 and an outside diameter 48. By way of example, prosthesis 20 can be approximately 80 mm in overall length with a nominal inside diameter of approximately 9.0 to 9.2 mm. Depending on how the prosthesis 20 is assembled and loaded into a delivery system, the diameters of the inner and outer stent along with that of the multilayered tissue construct can be selected to provide different compressive forces for the tissue construct. In a preferred embodiment of the present invention, inner stent 21 has a nominal inside diameter of approximately 10 mm in a fully relaxed condition, whereas the nominal inside diameter of outer stent 44 is approximately 9 mm in a fully relaxed condition. In this preferred method of assembly of prosthesis 20, inner stent 21 is radially compressed and inserted into a lyophilized tubular tissue construct 33 having a nominal diameter of approximately 9.5 mm. The tissue construct is then radially compressed and inserted into outer expandable stent 44 having a nominal inside diameter of approximately 9.0 mm. The ends of the inner and outer stents along with those of the tissue construct are adjusted so as to be coincident with each other. The prosthesis is then radially compressed for loading into a delivery system. Radial compression of the prosthesis can be achieved with the use of such commercially available equipment such as the SC200MSI Stent Pre-Reduction Equipment (PTA) provided by Machine Solutions, Inc., Phoenix, AZ. Other methods of radially compressing the prosthesis without damaging the construct are also contemplated, such as flattening the tubular tissue construct, inserting the folded construct into the outer stent, and then inserting the inner stent into the folded construct and outer stent. Thus, the construct is only compressed once for loading into the delivery system. After radial compression, the prosthesis is loaded into a delivery system.

- 20 -

Fig. 9 depicts an enlarged and partially sectioned view of the distal end portion of prosthesis delivery system 73 of the present invention. This prosthesis delivery system is commercially available as the FLEXOR® delivery system from COOK, Inc., Bloomington, Indiana. This delivery system is an over the wire system that is positioned at a placement site with the use of a well-known wire guide. A detailed description of a comparable medical device delivery system is provided in US Patent Application Ser. No. 60/338,714, filed November 29, 2001, also Publication No. US-2003-0144670-A1 and entitled "Medical Device Delivery System," which is incorporated herein by reference in its entirety. Prosthesis delivery system 73 includes delivery catheter 74 including a radiopaque marker 84 positioned about its distal end. This delivery catheter is flexible and kink resistant and is described in detail in U.S. Patents 5,380,304 and 5,700,253, entitled "A Flexible, Kink-Resistant Introducer Sheath and Method of Manufacture," which is incorporated by reference herein in its entirety. This delivery catheter is commercially available as the FLEXOR® introducer sheath from COOK, Inc., Bloomington, Indiana. The delivery catheter maintains prosthesis 20 in a radially compressed state or condition around inner member 75 of the prosthesis delivery system. Inner member 75 extends through and beyond the distal end of the delivery catheter. Inner member 75 includes a distal tip portion 78, a proximal portion 79, and an intermediate portion 80 disposed between the distal tip portion and the proximal portion. Prosthesis 20 is positioned around the recessed intermediate portion for containment therearound by delivery catheter 74. Inner member 75 includes an inner tube 76 such as a stainless steel cannula that connects to and extends proximally from the distal tip portion 78 to the proximal end of the inner member. Engagement portion 81, for example, comprising a radiopaque sleeve is positioned at the proximal end of the intermediate portion and maintained in position thereat by polymer material sleeve 82 such as commercially available heat shrink tubing. The outer diameter of sleeve 82 is heat shrunk to a size that very closely approximates the diameter of the inner lumen of the delivery catheter. An optional radiopaque marker sleeve 83 can be used to radiographically better visualize the engagement portion of the inner member. Furthermore,

- 21 -

engagement sleeve 82 abuts the proximal end of the prosthesis and closely approximates the diameter of the inner lumen of the delivery catheter so as to prevent the prosthesis from moving longitudinally as the delivery catheter is withdrawn from the prosthesis. The use of the terms "distal" and "proximal" are referenced from typically two different reference sources. The vascular medical community will typically reference a device from the heart. Thus, "distal" with respect to an implanted medical device such as, for example, the disclosed prosthesis is farthest from the heart, while "proximal" is closest to the heart. The rest of the medical community typically references "distal" and "proximal" with respect to the attending physician as such, for example, the disclosed delivery system, which is directly opposite to that of the heart.

To load prosthesis 20 into delivery system 73, inner tube 76 of the delivery system is positioned in the lumen or longitudinal passage of prosthesis 20 that has been radially compressed. The length of inner tube 76 extends into the passage of the prosthesis without distal tip portion 78 affixed thereto. After the inner tube is positioned in the compressed prosthesis, the proximal end of the prosthesis is pushed into the lumen of delivery catheter 24 until it reaches engagement portion 81 of the inner member. After the prosthesis is fully positioned in the delivery catheter and around intermediate portion 80 of the inner member, the length of inner tube 76 is then trimmed so as to permit distal tip portion 78 to be inserted over the distal end of the inner tube as indicated by the arrow. A transverse hole or aperture 85 is positioned in the distal tip portion to allow a commercially available, biocompatible medical grade glue 86 to be inserted therein and thus cement the distal tip portion to the inner tube. As depicted, radiopaque marker 84 is positioned at the distal end of delivery catheter 74 so as to radiographically mark the distal end of the delivery catheter.

In another method of assembling prosthesis 20 and loading it into prosthesis delivery system 73, self-expanding inner stent 21 is selected to have an inside diameter of approximately 9.0 mm, and multilayered tissue construct 33 is selected to have an inside diameter of approximately 9.5 mm. The inner stent is compressed and inserted into the hydrated multilayered tissue construct and

- 22 -

expanded to engage the hydrated construct. The inner stent and the hydrated tissue construct are then compressed to a diameter for insertion into the delivery catheter. Compressing the inner stent and hydrated tissue construct minimizes, if not eliminates, damage to the hydrated tissue construct. The compressed inner
5 stent and hydrated tissue construct are then frozen into a compressed diameter cylindrical solid. The outer stent 48 is then compressed around the solid, and the combination loaded into the delivery catheter over the inner tube as previously described. The distal tip portion of the inner member is then attached to the inner tube. After the prosthesis has been loaded into the delivery catheter including the
10 compressed diameter solid, the prosthesis delivery system is placed in a vacuum chamber to complete the lyophilization of the frozen tissue construct.

Fig. 10 depicts a pictorial view of yet another illustrative embodiment of stent tissue graft prosthesis 89 of the present invention. In this illustrative embodiment, prosthesis 89 comprises two inner stents 21 that are positioned end
15 to end to form a prosthesis that is the sum total length of the two inner stents. By way of example, the ZILVER stent available from COOK, Inc., Bloomington, Indiana, is commercially available in lengths from 20 to 80 mm in 10 mm increments with the stent diameter ranging from 6.0 to 10.0 mm in 1.0 mm increments. Stent diameters of 12 and 14 mm are also contemplated. Accordingly, the present
20 illustrative embodiment incorporates the use of two 80 mm long inner stents 21 positioned in a multilayered tissue construct 33 of approximately 160 mm. This multilayered tissue construct as previously described can include two or more layers of seamless tubes of juvenile SIS tissue. The construct can also include a wrapped sheet of mature SIS tissue. However, the present best mode embodiment
25 would include a multi-layered laminate construct of mature SIS tissue only. To complete stent tissue graft prosthesis 89, three outer expandable stents 44 are positioned over the inner stents and the tissue construct such as to stagger the abutment of the two end to end inner stents. Thus, by way of example, three outer stents 44 each having a length of approximately 53 mm and a diameter of 9.0 mm
30 could be utilized to complete the prosthesis. Alternatively, two standard length 60

- 23 -

mm stents in combination with a 40 mm in length stent could be used to complete the prosthesis.

Fig. 11 depicts a pictorial view of still yet another illustrative embodiment of stent tissue graft prosthesis 90 of the present invention. In this illustrative embodiment, prosthesis 90 includes two end to end inner expandable stents 21 partially covered by multilayered tissue construct 33. Prosthesis 90 thus has the inner stents 21 extending beyond the ends of the tissue construct such as to allow, for example, blood flow therethrough and into branch vessels of which the prosthesis can be positioned thereacross. To retain the multilayered tissue construct on the abutting inner stents, an outer expandable stent 44 is positioned over the entire length of the tissue construct so as to prevent eversion or fold back of the tissue construct during placement in a vessel. These combinations of various length inner and outer expandable stents in combination with a multilayered tissue construct can be customized to meet a host of different anatomical sites. The ends of inner and outer stents can also be tapered to different diameters for easy adjustment to fit different aortic or iliac diameters.

Fig. 12 depicts a pictorial view of still yet another illustrative embodiment of stent tissue graft prosthesis 91 of the present invention for use, by way of example, in a bifurcated vessel application. In this embodiment, prosthesis 91 includes an inner expandable stent 21 disposed next to drum graft occluder 92 with multilayered tissue construct 33 partially covering inner expandable stent 21 and completely covering occluder 92. Outer expandable stent 44 completely covers multilayered tissue construct 33. Drum draft occluder 92 typically comprises a tubular frame or stent with two coverings of a blood impermeable material transversely mounted on the ends of the frame. Two apertures are provided in each of the coverings to allow another prosthesis to be positioned through an aperture in each of the two coverings as will be detailed hereinafter. A detailed description of occluder 92 is provided in U.S. Patent No. 6,325,819, which is incorporated by reference herein in its entirety. As previously suggested, inner stent 21 extends beyond the end of tissue construct 33 and outer expandable stent 44 for allowing blood flow to branch vessels when positioned at a vascular site.

- 24 -

Figs. 13 and 14 depict a cross sectional view of abdominal aortic aneurysm 98 that is positioned in aorta 93 between renal arteries 96 and 97 and iliac arteries 94 and 95. Figs. 13 and 14 further depict the placement of bifurcated stent tissue graft prosthesis 91 in the aortic vessel and across aneurysm 98 so as to exclude the aneurysm from blood flow through the aortic vessel. Prosthesis 91 is intraluminally positioned across aneurysm 98 using a well-known minimally invasive surgically procedure via a cut-down or percutaneous insertion into the femoral arteries. In this surgical procedure, well-known and commercially available wire guides 101 and 102 are positioned through the ipsilateral and contralateral iliacs 94 and 95. In a multi-stent procedure, main body prosthesis 91 is first positioned across aneurysm 91 over a wire guide 101 via the ipsilateral iliac 94. After placement across the aneurysm, contralateral wire guide 102 is positioned through the main body prosthesis and the apertures of the occluder as shown via the contralateral iliac. As depicted in Fig. 14, an ipsilateral limb extension prosthesis 100 is inserted through the apertures of the occluder of the main body prosthesis via wire guide 101. Ipsilateral prosthesis 100 extends through the occluder of the main body prosthesis at its proximal end and extends at its distal end into ipsilateral iliac 94. Similarly, contralateral limb extension prosthesis 99 extends at its proximal end through the occluder and into the upper portion of main body prosthesis 91. At its distal end, prosthesis 99 extends into contralateral iliac 95.

Thus, it should be apparent that the stent tissue graft prosthesis of the present invention can be configured into a number of different embodiments to meet the anatomical needs of a patient by various combinations of the inner stent, multilayered tissue construct and outer stent. Multiple inner and outer stents can be used to form combination prosthesis with portions of the stent covered and uncovered to again meet the needs of the patient. As further depicted, occluders such as previously detailed as well as a square stent adapter can be utilized to form bifurcated versions of the stent tissue graft prosthesis. By way of example, a square stent adapter is described in detail in U.S. Patent No. 6,220,336, entitled "Multiple-Sided Intraluminal Medical Device," and published U.S. Patent Appl. No.

- 25 -

2001/0039450 entitled "Implantable Vascular Device," both of which are incorporated herein by reference in their entirety.

For ease of understanding, a list of elements used in the description and drawings of the present invention is included herewith. However, this element list
 5 is not to be construed to limit the present invention, but is only being provided for illustrative purposes and not to restrict the scope of the invention.

ELEMENT LIST

	20	stent tissue graft prosthesis
	21	first or inner expandable stent
10	22	tubular wall of 21
	23	passage of 21
	24	tissue graft
	25	tubular member
	26	wall of 25
15	27	passage of 25
	28	distal stent end of 21
	29	proximal stent end of 21
	30	distal graft end of 24
	31	proximal graft end of 24
20	32	at least one seamless tube of tissue of 24
	33	multilayered tissue construct of 24
	34	plurality of seamless tubes of tissue of 24
	35	sheet of tissue of 33
	36	extracellular matrix (ECM) material of 24
25	37	small intestine submucosa (SIS) of 24
	38	first diameter tube of 34
	39	second diameter tube of 34
	40	self-expanding stent
	41	balloon expandable stent
30	42	hoop cell segments of 21
	43	tie bars of inner stent 21
	44	second or outer expandable stent
	45	first stent inside diameter

- 26 -

	46	second stent inside diameter
	47	first stent outside diameter
	48	second stent outside diameter
	49	perforated polymer material
5	50	serpentine pattern
	51	plurality of straight struts
	52	plurality of bends
	53	construct wall of 33
	54	construct passage of 33
10	55	distal tubular (second stent) or outer stent end of 44
	56	proximal tubular (second stent) or outer stent end of 44
	57	circumferential cell segments of 44
	58	tie bars of 44
	59	zigzag or Z pattern of 50
15	60	tie bars of 44
	61	distal end cell segment of 44
	62	proximal end cell segment of 44
	63	distal end cell segment of 21
	64	flex cell segment of 21
20	65	circumferential cell segments of 21
	66	eyelets
	67	second intermediate seamless tube of juvenile SIS tissue.
	68	outermost seamless tube of juvenile SIS tissue
	69	first layer of mature SIS tissue
25	70	second layer of mature SIS tissue
	71	flexible interconnection cell segment of 44
	72	hoop cell segment of 44
	73	prosthesis delivery system
	74	delivery catheter
30	75	inner member
	76	inner tube
	77	not used
	78	distal tip portion
	79	proximal portion

- 27 -

	80	intermediate portion
	81	engagement portion
	82	sleeve
	83	radiopaque sleeve of 75
5	84	radiopaque marker of 74
	85	distal tip aperture
	86	glue
	87	outer edge of 70
	88	inner edge of 69
10	89	prosthesis
	90	prosthesis
	91	prosthesis
	92	drum graft occluder
	93	aorta
15	94	ipsilateral iliac
	95	contralateral iliac
	96	ipsilateral renal
	97	contralateral renal
	98	aneurysm
20	99	contralateral limb extension prosthesis
	100	ipsilateral limb extension prosthesis
	101	wire guide
	102	wire guide

It is to be understood that the above-described tissue graft prosthesis and
 method of assembly and use are merely illustrative embodiments of the principles
 of this invention. However, the invention should not be construed as limited to the
 particular embodiments discussed. Instead, the above-described embodiments
 should be regarded as illustrative rather than restricted. For example, as
 mentioned above, outer tubular member 24 has been described as an outer
 expandable stent 44. Other embodiments of the tubular member may include a
 polymeric tubular member in which perforations are formed therein by, for
 example, laser cutting and the like, for allowing host tissue to come in direct contact

- 28 -


with the multilayered tissue construct for remodeling host tissue. This tubular member may be formed from any biocompatible material and is contemplated that such a tubular sleeve is fully within the limits of the claimed invention as follows.


Claims


1. A stent tissue graft prosthesis comprising a first expandable stent having a tubular wall and a passage extending longitudinally therethrough, and a tissue graft disposed on said first stent, characterized in that the prosthesis further
5 comprises a tubular member having a wall and a passage extending longitudinally therethrough, said tubular member being disposed over said tissue graft and around said first stent and retaining said tissue graft disposed on said first stent.
2. The prosthesis of claim 1, characterized in that said first stent has a first distal stent end and a first proximal stent end, and in that said tissue graft has a
10 distal graft end and a proximal graft end, each of which is disposed on said first stent and at most up to and including at least one of said first distal and said first proximal stent ends, respectively.
3. The prosthesis of claim 1, characterized in that said tissue graft includes at least one of a seamless tube of tissue, a multilayered tissue construct, or a sheet
15 of tissue.
4. The prosthesis of claim 3, characterized in that said tissue graft includes an extracellular matrix material, preferably small intestine submucosa.
5. The prosthesis of claim 3, characterized in that said multilayered tissue construct includes a plurality of laminated tissue layers ranging from preferably two
20 to ten layers, more preferably two to six layers, and even more preferably four layers.
6. The prosthesis of claim 1, characterized in that said first expandable stent is a self-expanding, a balloon expandable stent or a combination self-expanding and balloon expandable stent.
- 25 7. The prosthesis of claim 1, characterized in that said first expandable stent has a plurality of circumferential segments and a plurality of tie bars longitudinally interconnecting said plurality of circumferential segments.
8. The prosthesis of claim 1, characterized in that said tubular member comprises a second expandable stent that is self-expanding, balloon expandable
30 or a combination of both.


- 30 -

9. The prosthesis of claim 8, characterized in that each of said first and said second stents has an inside diameter and an outside diameter and in that said first stent in a relaxed condition has an outside diameter less than equal to or greater than an inside diameter of said second stent in a relaxed condition.
- 5 10. The prosthesis of claim 1, characterized in that said tubular member comprises a perforated polymer material.
11. The prosthesis of claim 1, characterized in that said tubular member is disposed completely over said tissue graft.
- 10 12. The prosthesis of claim 1, characterized in that at least one end of said first stent extends beyond at least one end of said tissue graft.









5/10




FIG. 5







Fig. 6



8/10



9/10




FIG. 10




FIG. 11

10/10




FIG. 14




FIG. 13




FIG. 12

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 03/37365

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 916 264 A (VON OEPEN RANDOLF ET AL) 29 June 1999 (1999-06-29)	1,3,6-9, 12
Y	column 1, line 29 -column 2, line 34 ----	2,4,5, 10,11
X	WO 97 24081 A (LOVE CHARLES S ;RAMUS MEDICAL TECHNOLOGIES (US)) 10 July 1997 (1997-07-10)	1,3,6-9
Y	page 4, line 12 -page 16, line 12 figures 9,10 ----	2,4,5, 10,11
Y	WO 02 089707 A (CLERC CLAUDE O ;BIONX IMPLANTS INC (US)) 14 November 2002 (2002-11-14) figure 2A ----- -/-	2

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

30 March 2004

Date of mailing of the international search report

06/04/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Skorovs, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/37365

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01 82836 A (UNIV OREGON HEALTH SCIENCES) 8 November 2001 (2001-11-08) page 1, line 1 -page 9, line 3 -----	4,5
Y	US 6 334 868 B1 (HAM KEVIN) 1 January 2002 (2002-01-01) column 1, line 62 -column 3, line 67 figure 2 -----	10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/37365

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5916264	A	29-06-1999	DE 19720115 A1	24-12-1998
			AT 195239 T	15-08-2000
			CA 2224548 A1	14-11-1998
			DK 878173 T3	27-12-2000
			EP 0878173 A1	18-11-1998
			ES 2151218 T3	16-12-2000
			GR 3034716 T3	31-01-2001
			JP 3211156 B2	25-09-2001
			JP 10314313 A	02-12-1998
			PT 878173 T	30-11-2000
WO 9724081	A	10-07-1997	US 5865723 A	02-02-1999
			AU 720362 B2	01-06-2000
			AU 1569297 A	28-07-1997
			CA 2240989 A1	10-07-1997
			EP 0874603 A1	04-11-1998
			JP 2000502586 T	07-03-2000
			WO 9724081 A1	10-07-1997
WO 02089707	A	14-11-2002	US 2002165601 A1	07-11-2002
			WO 02089707 A1	14-11-2002
WO 0182836	A	08-11-2001	AU 6120001 A	12-11-2001
			CA 2403276 A1	08-11-2001
			EP 1278482 A2	29-01-2003
			JP 2003531674 T	28-10-2003
			WO 0182836 A2	08-11-2001
			US 2001041928 A1	15-11-2001
US 6334868	B1	01-01-2002	NONE	